Head-to-head evidence
ORKA-002 vs sonelokimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-17A/F · full Psoriasis pipeline
ORKA-002
Developed by Oruka Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2027 · NCT07474792 (registry estimate)
sonelokimab
Developed by MoonLake Immunotherapeutics
NCT03384745 · Phase 2 · completed
This was a well-powered, randomized, blinded, placebo-controlled trial using a validated skin-clearance measure as its primary endpoint, and every sonelokimab dose group achieved a substantially and statistically significantly higher clear/almost-clear skin rate than placebo at week 12.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ORKA-002's landscape · sonelokimab's landscape